# Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination

> **NCT03576313** · PHASE3 · COMPLETED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 4939 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** dihydroartemisinin-piperaquine (DP)
- **DRUG:** ivermectin (IVM)
- **OTHER:** standard malaria control interventions only

## Key facts

- **NCT ID:** NCT03576313
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-11
- **Primary completion:** 2019-12-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 4939 (ACTUAL)
- **Last updated:** 2022-03-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576313, "Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03576313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*